PARP-1 Modulates Amyloid Beta Peptide-Induced Neuronal Damage

PLoS ONE

Volumn 8, Issue 9, 2013, Pages

  Martire, Sara ^a   Fuso, Andrea ^a   Rotili, Dante ^a   Tempera, Italo ^b   Giordano, Cesare ^a   De Zottis, Ivana ^a   Muzi, Alessia ^c   Vernole, Patrizia ^c   Graziani, Grazia ^c   Lococo, Emanuela ^d   Faraldi, Martina ^a   Maras, Bruno ^a   Scarpa, Sigfrido ^a   Mosca, Luciana ^a   d'Erme, Maria ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF ROME TOR VERGATA   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[25-35]; AMYLOID PRECURSOR PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; PROTEIN BCL 2; PROTEIN P53;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL FRACTIONATION; CELL VIABILITY; COLORIMETRY; CONTROLLED STUDY; CYTOTOXICITY; DNA DAMAGE; ENZYME ACTIVITY; FEMALE; GEL MOBILITY SHIFT ASSAY; GENE TRANSLOCATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MEMBRANE PERMEABILITY; MOUSE; NERVE DEGENERATION; NEUROBLASTOMA CELL; NONHUMAN; OXIDATIVE STRESS; PROTEIN ANALYSIS; PROTEIN FUNCTION;

AMYLOID BETA-PEPTIDES; ANIMALS; BASE SEQUENCE; CELL LINE; CHO CELLS; COMET ASSAY; CRICETINAE; CRICETULUS; DNA DAMAGE; DNA PRIMERS; ELECTROPHORETIC MOBILITY SHIFT ASSAY; MICE; MICE, TRANSGENIC; NEURONS; PEPTIDE FRAGMENTS; POLY(ADP-RIBOSE) POLYMERASES; REACTIVE OXYGEN SPECIES;

EID: 84884573236     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0072169     Document Type: Article

References (66)

1. Butterfield DA, (2002) Amyloid beta-peptide (1-42)-induced oxidative stress and neurotoxicity: implications for neurodegeneration in Alzheimer's disease brain. A review. Free Radic Res 36: 1307-13.
2. Hayashi M, (2009) Oxidative stress in developmental brain disorders. Neuropathology 29: 1-8.
3. Harper JD, Wong SS, Lieber CM, Lansbury PT, (1999) Assembly of Abeta amyloid protofibrils: an in vitro model for a possible early event in Alzheimer's disease. Biochemistry 38: 8972-80.
4. Larson ME, Lesné SE, (2012) Soluble Aβ oligomer production and toxicity. J Neurochem 120Suppl 1: 125-39.
5. Barnham KJ, Masters CL, Bush AI, (2004) Neurodegenerative diseases and oxidative stress. Nat Rev Drug Discov 3: 205-14.
6. Smith DG, Cappai R, Barnham KJ, (2007) The redox chemistry of the Alzheimer's disease amyloid beta peptide. Biochim Biophys Acta 1768: 1976-90.
7. Wilkinson BL, Landreth GE, (2006) The microglial NADPH oxidase complex as a source of oxidative stress in Alzheimer's disease. J Neuroinflamm 3: 30.
8. Ji Y, Tulin AV, (2010) The roles of PARP1 in gene control and cell differentiation. Curr Opin Genet Dev 20: 512-8.
9. D'Amours D, Desnoyers S, D'Silva I, Poirier GG, (1999) Poly (ADP-ribosyl) ation reactions in the regulation of nuclear functions. Biochem J 342: 249-68.
10. de la Lastra CA, Villegas I, Sánchez-Fidalgo S, (2007) Poly (ADP-ribose) polymerase inhibitors: new pharmacological functions and potential clinical implications. Curr Pharm Des 13: 933-62.
11. Kauppinen TM, Swanson RA, (2007) The role of poly (ADP-ribose) polymerase-1 in CNS disease. Neuroscience 145: 1267-72.
12. Pacher P, Szabó C, (2005) Role of poly (ADP-ribose) polymerase-1 activation in the pathogenesis of diabetic complications: endothelial dysfunction, as a common underlying theme. Antiox Redox Signal 7: 1568-80.
13. Peralta-Leal A, Rodríguez-Vargas JM, Aguilar-Quesada R, Rodríguez MI, Linares JL, et al. (2009) PARP inhibitors: new partners in the therapy of cancer and inflammatory diseases. Free Radic Biol Med 47: 13-26.
14. Strosznajder RP, Jesko H, Zambrzycka A, (2005) Poly (ADP-ribose) polymerase: the nuclear target in signal transduction and its role in brain ischemia-reperfusion injury. Mol Neurobiol 31: 149-67.
15. Tempera I, Deng Z, Atanasiu C, Chen CJ, D'Erme M, et al. (2010) Regulation of Epstein-Barr virus OriP replication by poly (ADP-ribose) polymerase 1. J Virol 84: 4988-97.
16. Love S, Barber R, Wilcock GK, (1999) Increased poly (ADP-ribosyl) ation of nuclear proteins in Alzheimer's disease. Brain 122: 247-53.
17. Mandir AS, Przedborski S, Jackson-Lewis V, Wang ZQ, Simbulan-Rosenthal CM, et al. (1999) Poly (ADP-ribose) polymerase activation mediates 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism. Proc Natl Acad Sci USA 96: 5774-9.
18. Strosznajder JB, Jeśko H, Strosznajder RP, (2000) Effect of amyloid beta peptide on poly (ADP-ribose) polymerase activity in adult and aged rat hippocampus. Acta Biochim Pol 47: 847-54.
19. Mosca L, Rotili D, Tempera I, Masci A, Fontana M, et al. (2011) Biological effects of MC2050, a quinazoline-based PARP-1 inhibitor, in human neuroblastoma and EBV-positive Burkitt's lymphoma cells. ChemMedChem 6: 606-11.
20. Atherton E, Sheppard RC (1989) Solid Phase Synthesis - A Practical Approach. IRL Press at Oxford University Press, USA. p. 203.
21. Chishti MA, Yang DS, Janus C, Phinney AL, Horne P, et al. (2001) Early-onset amyloid deposition and cognitive deficits in transgenic mice expressing a double mutant form of amyloid precursor protein 695. J Biol Chem 276: 21562-70.
22. Xie HR, Hu LS, Li GY, (2010) SH-SY5Y human neuroblastoma cell line: in vitro cell model of dopaminergic neurons in Parkinson's disease. Chin Med J 123: 1086-92.
23. Zabel U, Schreck R, Baeuerle PA, (1991) DNA binding of purified transcription factor NF-kappa B. Affinity, specificity, Zn2+ dependence, and differential half-site recognition. J Biol Chem 266: 252-60.
24. Poojari C, Kukol A, Strodel B, (2012) How the amyloid-β peptide and membranes affect each other: An extensive simulation study. Biochim Biophys Acta 1828: 327-39.
25. Tofoleanu F, Buchete NV, (2012) Molecular interactions of Alzheimer's Aβ protofilaments with lipid membranes. J Mol Biol 421: 572-86.
26. Kuner P, Schubenel R, Hertel C, (1998) Beta-amyloid binds to p57NTR and activates NFkappaB in human neuroblastoma cells. J Neurosci Res 54: 798-804.
27. Valerio A, Boroni F, Benarese M, Sarnico I, Ghisi V, et al. (2006) NF-kappaB pathway: a target for preventing beta-amyloid (Abeta)-induced neuronal damage and Abeta42 production. Eur J Neurosci 23: 1711-20.
28. Hassa PO, Covic M, Hasan S, Imhof R, Hottiger MO, (2001) The enzymatic and DNA binding activity of PARP-1 are not required for NF-kappa B coactivator function. J Biol Chem 276: 45588-97.
29. Zerfaoui M, Errami Y, Naura AS, Suzuki Y, Kim H, et al. (2010) Poly (ADP-ribose) polymerase-1 is a determining factor in Crm1-mediated nuclear export and retention of p65 NF-kappa B upon TLR4 stimulation. J Immunol 185: 1894-902.
30. Abd Elmageed ZY, Naura AS, Errami Y, Zerfaoui M, (2012) The poly (ADP-ribose) polymerases (PARPs): new roles in intracellular transport. Cell Signal 24: 1-8.
31. Bürkle A, (2005) Poly (ADP-ribose). The most elaborate metabolite of NAD+. FEBS J 272: 4576-89.
32. Shall S, de Murcia G, (2000) Poly (ADP-ribose) polymerase-1: what have we learned from the deficient mouse model? Mutat Res 460: 1-15.
33. Alano CC, Garnier P, Ying W, Higashi Y, Kauppinen TM, et al. (2010) NAD+ depletion is necessary and sufficient for poly (ADP-ribose) polymerase-1-mediated neuronal death. J Neurosci 30: 2967-78.
34. Mukhopadhyay P, Horváth B, Kechrid M, Tanchian G, Rajesh M, et al. (2011) Poly (ADP-ribose) polymerase-1 is a key mediator of cisplatin-induced kidney inflammation and injury. Free Radic Biol Med 51: 1774-88.
35. Czapski GA, Cakala M, Gajkowska B, Strosznajder JB, (2006) Poly (ADP-ribose) polymerase-1 inhibition protects the brain against systemic inflammation. Neurochem Int 49: 751-5.
36. d'Avila JC, Lam TI, Bingham D, Shi J, Won SJ, et al. (2012) Microglial activation induced by brain trauma is suppressed by post-injury treatment with a PARP inhibitor. J Neuroinflamm 15: 9-31.
37. Pellicciari R, Camaioni E, Costantino G, (2004) Life or death decisions: the cast of poly (ADP-ribose) polymerase (PARP) as a therapeutic target for brain ischaemia. Prog Med Chem 42: 125-69.
38. Abeti R, Duchen MR, (2012) Activation of PARP by oxidative stress induced by β-Amyloid: implications for Alzheimer's Disease. Neurochem Res 37: 2589-96.
39. Strosznajder JB, Czapski GA, Adamczyk A, Strosznajder RP, (2012) Poly (ADP-ribose) polymerase-1 in amyloid beta toxicity and Alzheimer's disease. Mol Neurobiol 46: 78-84.
40. Atwood CS, Moir RD, Huang X, Scarpa RC, Bacarra NM, et al. (1998) Dramatic aggregation of Alzheimer abeta by Cu (II) is induced by conditions representing physiological acidosis. J Biol Chem 273: 12817-26.
41. Cai Z, Zhao B, Ratka A, (2011) Oxidative stress and β-amyloid protein in Alzheimer's disease. Neuromol Med 13: 223-50.
42. Millucci L, Raggiaschi R, Franceschini D, Terstappen G, Santucci A, (2009) Rapid aggregation and assembly in aqueous solution of A beta (25-35) peptide. J Biosci 34: 293-303.
43. Kaminsky YG, Marlatt MW, Smith MA, Kosenko EA, (2010) Subcellular and metabolic examination of amyloid-beta peptides in Alzheimer disease pathogenesis: evidence for Abeta (25-35). Exp Neurol 221: 26-37.
44. Frozza RL, Horn AP, Hoppe JB, Simão F, Gerhardt D, et al. (2009) A comparative study of beta-amyloid peptides Abeta1-42 and Abeta25-35 toxicity in organotypic hippocampal slice cultures. Neurochem Res 34: 295-303.
45. Abramov AY, Canevari L, Duchen MR, (2004) Beta-amyloid peptides induce mitochondrial dysfunction and oxidative stress in astrocytes and death of neurons through activation of NADPH oxidase. J Neurosci 24: 565-75.
46. Olivieri G, Baysang G, Meier F, Muller-Spahn F, Stahelin HB, et al. (2001) N-acetyl-L-cysteine protects SHSY5Y neuroblastoma cells from oxidative stress and cell cytotoxicity: effects on beta-amyloid secretion and tau phosphorylation. J Neurochem 76: 224-33.
47. Chiarugi A, Moskowitz MA, (2003) Poly (ADP-ribose) polymerase-1 activity promotes NF-kappaB-driven transcription and microglial activation: implication for neurodegenerative disorders. J Neurochem 85: 306-17.
48. Datki Z, Juhász A, Gálfi M, Soós K, Papp R, et al. (2003) Method for measuring neurotoxicity of aggregating polypeptides with the MTT assay on differentiated neuroblastoma cells. Brain Res Bull 62: 223-9.
49. Kang YH, Yi MJ, Kim MJ, Park MT, Bae S, et al. (2004) Caspase-independent cell death by arsenic trioxide in human cervical cancer cells: reactive oxygen species-mediated poly (ADP-ribose) polymerase-1 activation signals apoptosis-inducing factor release from mitochondria. Cancer Res 64: 8960-7.
50. Szabó C, (1996) The pathophysiological role of peroxynitrite in shock, inflammation, and ischemia-reperfusion injury. Shock 6: 79-88.
51. Abeti R, Abramov AY, Duchen MR, (2011) Beta-amyloid activates PARP causing astrocytic metabolic failure and neuronal death. Brain 134: 1658-72.
52. Beneke S, (2012) Regulation of chromatin structure by poly (ADP-ribosyl) ation. Front Genet 3: 169.
53. Chang WJ, Alvarez-Gonzalez R, (2001) The sequence-specific DNA binding of NF-kappa B is reversibly regulated by the automodification reaction of poly (ADP-ribose) polymerase 1. J Biol Chem 276: 47664-70.
54. Gilmore TD, (1999) The Rel/NF-kappaB signal transduction pathway: introduction. Oncogene 18: 6842-4.
55. Perkins N, (2006) Post-translational modifications regulating the activity and function of the nuclear factor kappa B pathway. Oncogene 25: 6717-30.
56. Patel JR, Brewer GJ, (2008) Age-related differences in NFkappaB translocation and Bcl-2/Bax ratio caused by TNFalpha and Abeta42 promote survival in middle-age neurons and death in old neurons. Exp Neurol 213: 93-100.
57. Checler F, Sunyach C, Pardossi-Piquard R, Sevalle J, Vincent B, et al. (2007) The gamma/epsilon-secretase-derived APP intracellular domain fragments regulate p53. Curr Alzheimer Res 4: 423-6.
58. Maki CG, Huibregtse JM, Howley PM, (1996) In vivo ubiquitination and proteasome-mediated degradation of p53 (1). Cancer Res 56: 2649-54.
59. Chen JJ, Lin F, Qin ZH, (2008) The roles of the proteasome pathway in signal transduction and neurodegenerative diseases. Neurosci Bull 24: 183-94.
60. Wesierska-Gadek J, Schmid G, (2001) Poly (ADP-ribose) polymerase-1 regulates the stability of the wild-type p53 protein. Cell Mol Biol Lett 6: 117-40.
61. Wieler S, Gagné JP, Vaziri H, Poirier GG, Benchimol S, (2003) Poly (ADP-ribose) polymerase-1 is a positive regulator of the p53-mediated G1 arrest response following ionizing radiation. J Biol Chem 278: 18914-21.
62. Valenzuela MT, Guerrero R, Núñez MI, Ruiz De Almodóvar JM, Sarker M, et al. (2002) PARP-1 modifies the effectiveness of p53-mediated DNA damage response. Oncogene 21: 1108-16.
63. Song YS, Park HJ, Kim SY, Lee SH, Yoo HS, et al. (2004) Protective role of Bcl-2 on beta-amyloid-induced cell death of differentiated PC12 cells: reduction of NF-kappaB and p38 MAP kinase activation. Neurosci Res 49: 69-80.
64. Paradis E, Douillard H, Koutroumanis M, Goodyer C, LeBlanc A, (1996) Amyloid beta peptide of Alzheimer's disease downregulates Bcl-2 and upregulates bax expression in human neurons. J Neurosci 16: 7533-9.
65. Yang N, Gong F, Sun L, Yang D, Han X, et al. (2010) Poly (ADP-ribose) polymerase-1 binds to BCL2 major breakpoint region and regulates BCL2 expression. J Cell Biochem 110: 1208-18.
66. Dutta C, Day T, Kopp N, van Bodegom D, Davids MS, et al. (2012) BCL2 suppresses PARP1 function and nonapoptotic cell death. Cancer Res 72: 4193-203.